New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
10:01 EDTORMPOramed falls 12.4%
Oramed is down 12.4%, or $2.73, to $19.36
News For ORMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
08:34 EDTORMPOramed's oral insulin capsules show positive Phase IIa results
Oramed Pharmaceuticals reported positive top-line clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes. The trial was conducted in the U.S. under an FDA Investigational New Drug protocol. The prospective, randomized, double-blind, placebo controlled study evaluated the safety and impact of ORMD-0801 given before meals on the exogenous insulin requirements in 25 established type 1 diabetic patients. ORMD-0801 oral insulin given before meals appeared to be safe and well-tolerated. Although the study was not powered to show statistical significance, there were internally consistent trends observed. The data showed a decrease in rapid acting insulin, a decrease in post-prandial glucose, a decrease in daytime glucose by continual glucose monitoring and an increase in post-prandial hypoglycemia in the active group.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use